ReNeuron Group PLC - Bridgend, Wales-based stem cell and exosomes technology - Olav Hellobo resigns as chief executive officer after seven years and will leave at the end of February. Hellobo says he decided it was time to leave following ReNeuron's recent change in strategy. The company has shifted its focus to the development of its exosomes technology platform. The platform uses stem cell technologies to develop "off the shelf" treatments for diseases. Chair Iain Ross, supported by Chief Financial Officer Catherine Isted, will run the business, ReNeuron says.
Current stock price: 38.45 pence, up 11% on Friday
12-month change: down 67%
By Tom Waite; thomaslwaite@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)